Introduction In recent decades, significant advances have led to a complete reformulation of clinical and epidemiological concepts about cardiac transthyretin (ATTR) amyloidosis, summarized in . […]

Cardiac amyloidosis (CA) is a severe and progressive infiltrative disease caused by the deposition of amyloid fibrils, with poor prognosis and limited therapeutic options. It can occur due to rare genetic variants or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of obtaining non-invasive diagnosis, we now know that CA would perhaps be better classified as an underdiagnosed disease rather than as a rare one. – González-Lopez et al. demonstrated that, in a […]

Over the past years, the recognition of cardiac involvement due to deposition of amyloid substances has received greater emphasis. Cardiac amyloidosis (CA), as it is known, has been shown to be a more prevalent cause of heart failure with preserved ejection fraction than in previous decades, although diagnosis remains a constant challenge. With advances in pathophysiological knowledge of this disease, as well as relevant advances in diagnostic methods, particularly in the field of cardiovascular imaging, there has been a significant […]

Abstract A 90-year-old male patient presented with complaints and physical examination compatible with decompensated heart failure. Electrocardiogram showed atrial fibrillation and low voltage in limb leads, and echocardiogram identified biatrial dilatation, in addition to mild increases in ventricular wall thickness and diameter. Magnetic resonance imaging confirmed suspicion of cardiac amyloidosis. With negative serum and urinary protein electrophoresis and positive pyrophosphate cardiac scintigraphy, diagnosis of transthyretin cardiac amyloidosis was confirmed. Transthyretin gene mutations were not identified on sequencing, characterizing wild-type transthyretin […]